HHV-6B U20 protein inhibits NK cell attacks on virally-infected cells.
Part 1: Latent HHV-6 is reactivated in patients receiving CAR-T cell therapy
Investigators urge careful monitoring for HHV-6 and ciHHV-6.
Part 2: CAR-T cell therapy and its complications
Could some complications of CAR-T cell therapy be secondary to HHV-6 infection?
Part 3. HHV-6 Encephalitis in CAR-T Cell therapy
Clearly documented cases of HHV-6 encephalitis have been reported, but some are missed because they were classified as ICAN or because HHV-6 testing was not performed in patients with mental status changes.
Part 4. Might HHV-6 contribute to some cases of cytokine release syndrome, pneumonia, and cytopenias in CAR-T Cell therapy?
While unlikely to trigger the cytokine storm, HHV-6 infection may perpetuate it, and contribute directly to cytopenias and pneumonia.
Early HHV-6 specific T-cell responses by ELISpot were remarkably higher in alloHSCT patients who went on to develop clinically relevant infections
T-cell responses correlate directly with clinical symptoms, and were better predictors of HHV-6 disease than viral load or total CD3+ counts.
Adding an adoptive NK cell infusion to naïve T-Cell-depleted grafts may reduce the rate of HHV-6B reactivation and encephalitis
A small pediatric study found that adoptive NK cell infusions eliminated HHV-6B encephalitis, while maintaining a low rate of GVHD. At a ratio of NK/CD4 >2, the HHV-6B reactivation rate dropped dramatically.
Viral reactivation may be one cause of febrile neutropenia in chemotherapy patients
HHV-6 was the most prevalent virus in febrile neutropenia episodes among pediatric patients
The effects of HHV-6B infection on immune checkpoint inhibition
HHV-6B infection of primary monocytes induces cell-associated and soluble PD-L1 production, increased intracellular ROS and activation of STAT1 and STAT3 pathways
HHV-6 linked to intrauterine growth restriction via the human leukocyte antigen-G dysregulation
A small study found a strong association between HHV-6 infection of the placenta and intrauterine growth restriction—a finding consistent with other evidence linking HHV-6 to several reproductive diseases.
HHV-6A and 7 infection of T cells downregulates the protein tyrosine phosphatase, CD45
CD45, important in T cell receptor signaling, may be one mechanism by which roseolaviruses evade immune detection and help achieve latency
iciHHV-6 may modulate human gene expression
A Japanese group found that ciHHV6 genes encoding for immunoglobulins were decreased in ciHHV6 individuals, possibly modulating immune responses.
HHV-6A, HHV-6B, and HHV-7 have differential impact on intracellular DNA sensors of NK cells
Cytokine and chemokine responses were very similar in HHV-6B and HHV-7 infections. The results were starkly different for HHV-6A.
49 new CD4 T-cell-recognized HHV-6B antigens identified using genome-wide approach
University of Washington investigators utilized rare cell enrichment and an HLA-agnostic, proteome-wide approach to expand the library of known HHV-6 T cell antigens from 11 to 60.
New HLA-DR3-restricted HHV-6B peptides demonstrate broadly recognized polyfunctional and cytotoxic CD4 T-cell responses
University of Massachusetts investigators have identified 25 new naturally processed peptide sequences using mass spectrometry.
- Page 1 of 2
- 1
- 2